Radiosurgery For Brain Metastasis From Advanced Gastric CancerKeywords: gamma knife, cancer, brain metastasis, outcome, gastric cancerInteractive Manuscript
Ask Questions of this Manuscript:
What is the background behind your study?
Gastric cancer outcomes are less frequently reported than other cancer types.
What is the purpose of your study?
We retrospectively evaluated the survival of patients with brain metastases from advanced gastric cancer (AGC) after radiosurgery (RS).
Describe your patient group.
Between 1998 and 2007, a total of 11 patients (median age, 61 years; range, 36-70) were diagnosed with brain metastasis from AGC and treated with RS. Each of five (46%) patients had two brain metastases. The median volume of the 16 lesions was 2.9 cm3 (range, 0.1-33.8).
Describe what you did.
The median marginal dose prescribed was 20 Gy (range, 10-25) at the 50% isodose line. RS was the primary treatment for brain metastases in six patients.
Describe your main findings.
As of Feb 28, 2008, 8 (73%) patients had died and three (27%) were living with stable disease. The median survival time was 17.0±3.9 months (95% CI, 9.4-24.6). The median progression-free survival time was 9.0±2.5 months (95% CI, 4.2-13.8). Patients who did not undergo WBRT died within eight months, and the other six patients treated with WBRT at various time intervals from diagnosis of brain metastases survived, with a median survival time of 19.0±3.4 months (95% CI, 12.4-25.6).
Describe the main limitation of this study.
This is a retrospective study.
Describe your main conclusion.
Radiosurgery seems to be a good alternative to surgical resection for patients with brain metastases from AGC, when performed in conjunction with WBRT.
Describe the importance of your findings and how they can be used by others.
Although less common than other tumors, radiosurgery can be of value.
Gastric cancer outcomes are less frequently reported than other cancer types.
We retrospectively evaluated the survival of patients with brain metastases from advanced gastric cancer (AGC) after radiosurgery (RS).
Between 1998 and 2007, a total of 11 patients (median age, 61 years; range, 36-70) were diagnosed with brain metastasis from AGC and treated with RS. Each of five (46%) patients had two brain metastases. The median volume of the 16 lesions was 2.9 cm3 (range, 0.1-33.8).
The median marginal dose prescribed was 20 Gy (range, 10-25) at the 50% isodose line. RS was the primary treatment for brain metastases in six patients.
As of Feb 28, 2008, 8 (73%) patients had died and three (27%) were living with stable disease. The median survival time was 17.0±3.9 months (95% CI, 9.4-24.6). The median progression-free survival time was 9.0±2.5 months (95% CI, 4.2-13.8). Patients who did not undergo WBRT died within eight months, and the other six patients treated with WBRT at various time intervals from diagnosis of brain metastases survived, with a median survival time of 19.0±3.4 months (95% CI, 12.4-25.6).
This is a retrospective study.
Radiosurgery seems to be a good alternative to surgical resection for patients with brain metastases from AGC, when performed in conjunction with WBRT.
Although less common than other tumors, radiosurgery can be of value.
Project Roles:
